Role of liquid biopsy, analysis of circulating tumor cells and organoids in the diagnostic and therapy of upper-GI and hepato-pancreatico-bilary cancers (GI- and HPB-CA)
Not Applicable
Recruiting
- Conditions
- C15C16C22C23C24C25Malignant neoplasm of oesophagusMalignant neoplasm of stomachMalignant neoplasm of liver and intrahepatic bile ductsMalignant neoplasm of gallbladder
- Registration Number
- DRKS00022375
- Lead Sponsor
- niversitätsklinik für innere Medizin - Gastroenterologie, Klinikum Oldenburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Patients with GI- and HPB-CA
Exclusion Criteria
Patients with poor condition who cannot tolerate chemotherapy and targeted therapy.
Patients with impaired organ functions, heart failure (New York Heart Association III-IV), coronary heart disease, myocardial infarction within 6 months, severe cardiac arrhythmia and respiratory failure.
Patients diagnosed with other cancer within 5 years.
Patients who are pregnant or breastfeeding.
Patients enrolled in other clinical trials or incompliant of regular follow up.
Patients who did not provide an informed consent.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CTC counts at several timepoints, before/after endoscopy, before/after neoadjuvant therapy and before/after surgery as well as following up after 3 and 6 months.
- Secondary Outcome Measures
Name Time Method Assessment of apoptotic response and infiltration with immune cells in response to standard and immunotherapeutic regimens in tumour organoid cultures of GI-CA and HPB-CA